🟢 Vertex Pharmaceuticals is trading 5.8% up in pre-market after 12% revenue growth, higher 2026 guidance

Vertex Pharmaceuticals is trading +5.83% at $525.01 in pre-market as investors continued responding positively to its August 3 second-quarter report.

• Second-quarter revenue rose 12% to $3.33 billion, and full-year 2026 guidance increased to $13.1–$13.2 billion.
• The pending Crinetics acquisition adds a fifth disease-area pillar; UBS said Vertex remains well positioned ahead of second-half pipeline catalysts amid a modestly supportive Nasdaq backdrop.